Long/short equity, biotech, healthcare, small-cap

Why Genomic Health Is A Solid Long-Term Buy

Despite market concerns like emerging competition and low-entry barriers in the oncology treatment market, Genomic Health (GHDX) reported robust third-quarter earnings. It has strong growth potential in the international market, which is quickly becoming an important part of Genomic Health's growth story. I believe the underpenetrated market with thin competition should help Genomic Health continue its double-digit growth trajectory. With the NICE recommendation firmly in its pocket, Genomic Health should increase UK test volumes and prove its case successfully to other European countries, to incorporate the Oncotype DX Breast test. Additionally, seeing the growing unmet clinical need in prostate cancer, I believe Oncotype DX Prostate will also be a long-term growth driver for Genomic Health. With the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details